Alpha emitter radium-223 and survival in metastatic prostate cancer

C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, S D Fosså, A Chodacki, P Wiechno, J Logue, M Seke, A Widmark, D C Johannessen, P Hoskin, D Bottomley, N D James, A Solberg, I Syndikus, J Kliment, S Wedel, S BoehmerM Dall'Oglio, L Franzén, R Coleman, N J Vogelzang, C G O'Bryan-Tear, K Staudacher, J Garcia-Vargas, M Shan, Ø S Bruland, O Sartor, ALSYMPCA Investigators

Research output: Contribution to journalArticle

1696 Citations (Scopus)

Abstract

Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.
Original languageEnglish
Pages (from-to)213-23
Number of pages11
JournalNew England Journal of Medicine
Volume369
Issue number3
DOIs
Publication statusPublished - 18 Jul 2013

Keywords

  • Aged
  • Aged, 80 and over
  • Bone Neoplasms
  • Double-Blind Method
  • Humans
  • Isotopes
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prostatic Neoplasms
  • Radium

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Alpha emitter radium-223 and survival in metastatic prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., ... ALSYMPCA Investigators (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369(3), 213-23. https://doi.org/10.1056/NEJMoa1213755